WO1999027905A1 - Compositions for nasal administration - Google Patents
Compositions for nasal administration Download PDFInfo
- Publication number
- WO1999027905A1 WO1999027905A1 PCT/GB1998/003572 GB9803572W WO9927905A1 WO 1999027905 A1 WO1999027905 A1 WO 1999027905A1 GB 9803572 W GB9803572 W GB 9803572W WO 9927905 A1 WO9927905 A1 WO 9927905A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition according
- drug
- composition
- nasal
- apomorphine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Psychology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ504786A NZ504786A (en) | 1997-12-02 | 1998-11-27 | Sustained release compositions for nasal administration of drugs for treating erectile disfunction and parkinson's disease |
AU12535/99A AU751182B2 (en) | 1997-12-02 | 1998-11-27 | Compositions for nasal administration |
CA002312839A CA2312839C (en) | 1997-12-02 | 1998-11-27 | Compositions for nasal administration |
JP2000522892A JP4754067B2 (en) | 1997-12-02 | 1998-11-27 | Composition for nasal administration |
EP98955814A EP1035833B1 (en) | 1997-12-02 | 1998-11-27 | Compositions for nasal administration |
DE69831421T DE69831421T2 (en) | 1997-12-02 | 1998-11-27 | COMPOSITIONS FOR NASAL ADMINISTRATION |
AT98955814T ATE303131T1 (en) | 1997-12-02 | 1998-11-27 | COMPOSITIONS FOR NASAL ADMINISTRATION |
US09/586,139 US6342251B1 (en) | 1997-12-02 | 2000-06-02 | Compositions for nasal administration |
NO20002851A NO329381B1 (en) | 1997-12-02 | 2000-06-02 | Nasal administration compositions for the treatment of erectile dysfunction or Parkinson's disease |
US09/920,698 US20010046519A1 (en) | 1997-12-02 | 2001-08-01 | Compositions for nasal administration |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9725519.4 | 1997-12-02 | ||
GBGB9725519.4A GB9725519D0 (en) | 1997-12-02 | 1997-12-02 | Nasal formulation |
GB9805253.3 | 1998-03-13 | ||
GBGB9805253.3A GB9805253D0 (en) | 1998-03-13 | 1998-03-13 | Nasal formulation |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/586,139 Continuation US6342251B1 (en) | 1997-12-02 | 2000-06-02 | Compositions for nasal administration |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999027905A1 true WO1999027905A1 (en) | 1999-06-10 |
Family
ID=26312701
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1998/003572 WO1999027905A1 (en) | 1997-12-02 | 1998-11-27 | Compositions for nasal administration |
Country Status (13)
Country | Link |
---|---|
US (2) | US6342251B1 (en) |
EP (1) | EP1035833B1 (en) |
JP (2) | JP4754067B2 (en) |
AR (1) | AR017694A1 (en) |
AT (1) | ATE303131T1 (en) |
AU (1) | AU751182B2 (en) |
CA (1) | CA2312839C (en) |
DE (1) | DE69831421T2 (en) |
DK (1) | DK1035833T3 (en) |
ES (1) | ES2249846T3 (en) |
NO (1) | NO329381B1 (en) |
NZ (1) | NZ504786A (en) |
WO (1) | WO1999027905A1 (en) |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0967214A1 (en) * | 1998-06-22 | 1999-12-29 | Pfizer Limited | Intranasal formulations for treating sexual disorders |
WO1999066933A1 (en) * | 1998-06-25 | 1999-12-29 | New Millennium Pharmaceutical Research, Inc. | Nasal administration of sildenafil for the treatment of erectile dysfunction |
WO2000007596A1 (en) * | 1998-07-31 | 2000-02-17 | Hexal Ag | Water-soluble pharmaceutical formulation for administering sildenafil |
WO2000007597A1 (en) * | 1998-07-31 | 2000-02-17 | Hexal Ag | Transmucosal therapeutic system for administering sildenafil |
WO2000059491A2 (en) * | 1999-04-06 | 2000-10-12 | Zonagen, Inc. | Methods for modulating the human sexual response |
WO2000076509A1 (en) * | 1999-06-16 | 2000-12-21 | Nastech Pharmaceutical Company, Inc. | Nasal delivery of apomorphine |
WO2001074358A1 (en) * | 2000-03-20 | 2001-10-11 | Tap Pharmaceutical Products Inc. | Methods for treating sexual dysfunction with apomorphine at specified plasma concentration levels |
WO2002024202A1 (en) * | 2000-09-19 | 2002-03-28 | Nastech Pharmaceutical Company, Inc. | Nasal delivery of apomorphine in combination with glycol derivatives |
WO2002067897A2 (en) * | 2001-02-28 | 2002-09-06 | Carrington Laboratories, Inc. | In-situ gel formation of pectins |
US6506765B2 (en) | 2000-04-07 | 2003-01-14 | Tap Pharmaceutical Products, Inc. | Apomorphine derivatives and methods for their use |
WO2003080022A2 (en) * | 2002-03-19 | 2003-10-02 | Ionix Pharmaceuticals Limited | Analgesics for nasal administration |
JP2003534286A (en) * | 2000-05-26 | 2003-11-18 | ホーファー リサーチ リミテッド | Use of proanthocyanidin as an active ingredient of a stimulant and L-arginine or a salt thereof as a source of nitric oxide for improving erectile dysfunction symptoms |
EP1448194A1 (en) * | 2001-10-23 | 2004-08-25 | Pentech Pharmaceuticals, Inc. | Apomorphine-containing dosage form for ameliorating male erectile dysfunction |
WO2005041966A1 (en) * | 2003-10-24 | 2005-05-12 | Nastech Pharmaceutical Company Inc. | Treatment of parkinson's disease using apomorphine in combination with an apomorphine prodrug |
WO2007059390A1 (en) * | 2005-11-14 | 2007-05-24 | Medtronic Xomed, Inc. | Injectable formulation capable of forming a drug-releasing device |
US7498038B2 (en) | 2001-08-16 | 2009-03-03 | Cmp Therapeutics Limited | Chitin microparticles and their medical uses |
WO2009040595A1 (en) * | 2007-09-28 | 2009-04-02 | Wockhardt Research Centre | Multi-dose pharmaceutical composition of analgesic for nasal administration |
EP2057982A1 (en) | 2007-11-09 | 2009-05-13 | Archimedes Development Limited | Intranasal compositions |
WO2011063774A2 (en) | 2009-11-25 | 2011-06-03 | Zentiva, K.S. | Pectin complexes of steroids and pharmaceutical compositions based thereon |
US8889176B2 (en) | 2003-01-10 | 2014-11-18 | Depomed, Inc. | Method of managing or treating pain |
EP3056219A1 (en) * | 2015-02-12 | 2016-08-17 | Laboratoires Chemineau | Composition based on plants of the malvaceae family for mucosal delivery |
FR3032619A1 (en) * | 2015-02-12 | 2016-08-19 | Laboratoires Chemineau | PLANT-BASED COMPOSITION OF MALVACEAE FAMILY FOR NASAL CAVITY ADMINISTRATION |
US9700344B2 (en) | 2008-06-12 | 2017-07-11 | Medtronic Xomed, Inc. | Method for treating chronic wounds with an extracellular polymeric substance solvating system |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7022683B1 (en) * | 1998-05-13 | 2006-04-04 | Carrington Laboratories, Inc. | Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation |
US7258850B2 (en) * | 1999-05-04 | 2007-08-21 | Aradigm Corporation | Methods and compositions for treating erectile dysfunction |
US6632419B2 (en) * | 1999-05-04 | 2003-10-14 | Aradigm Corporation | Increasing libido in humans via acute testosterone administration |
US7494669B2 (en) * | 2001-02-28 | 2009-02-24 | Carrington Laboratories, Inc. | Delivery of physiological agents with in-situ gels comprising anionic polysaccharides |
US7923029B2 (en) * | 2002-04-11 | 2011-04-12 | Medimmune Llc | Spray freeze dry of compositions for pulmonary administration |
WO2003086443A1 (en) * | 2002-04-11 | 2003-10-23 | Medimmune Vaccines, Inc. | Spray freeze dry of compositions for intranasal administration |
EP1539208A2 (en) * | 2002-06-28 | 2005-06-15 | Nastech Pharmaceutical Company Inc. | Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds |
GB0304636D0 (en) * | 2003-02-28 | 2003-04-02 | Britannia Pharmaceuticals Ltd | Pharmaceutical composition for nasal delivery |
US20040204439A1 (en) * | 2003-04-14 | 2004-10-14 | Staniforth John Nicholas | Composition, device, and method for treating sexual dysfunction via inhalation |
US20060178394A1 (en) * | 2003-04-14 | 2006-08-10 | Staniforth John N | Pharmaceutical compositions comprising apomorphine for pulmonary inhalation |
WO2004098647A2 (en) * | 2003-04-30 | 2004-11-18 | Nastech Pharmaceutical Company Inc. | Claudins’ underexpression as markers of tumor metastasis |
US20050129679A1 (en) * | 2003-12-15 | 2005-06-16 | Nastech Pharmaceutical Company Inc. | Method for opening tight junctions |
WO2006085987A2 (en) * | 2004-07-09 | 2006-08-17 | University Of Iowa Research Foundation | Rna interference in respiratory epitheial cells |
NZ571965A (en) * | 2006-03-30 | 2012-02-24 | Engene Inc | Chitosan-based nanoparticles and methods for transfecting gut cells in vivo |
TWI496594B (en) | 2006-04-21 | 2015-08-21 | Toko Yakuhin Kogyo Kk | Gel-type formulation for spray adherable to skin/mucosa and administration system thereof |
GB2437488A (en) * | 2006-04-25 | 2007-10-31 | Optinose As | Pharmaceutical oily formulation for nasal or buccal administration |
US7959943B2 (en) * | 2006-05-10 | 2011-06-14 | Medtronics Xomed, Inc. | Solvating system and sealant for medical use in the middle or inner ear |
US7976873B2 (en) * | 2006-05-10 | 2011-07-12 | Medtronic Xomed, Inc. | Extracellular polysaccharide solvating system for treatment of bacterial ear conditions |
US20070264296A1 (en) * | 2006-05-10 | 2007-11-15 | Myntti Matthew F | Biofilm extracellular polysachharide solvating system |
US7993675B2 (en) * | 2006-05-10 | 2011-08-09 | Medtronic Xomed, Inc. | Solvating system and sealant for medical use in the sinuses and nasal passages |
US8088095B2 (en) * | 2007-02-08 | 2012-01-03 | Medtronic Xomed, Inc. | Polymeric sealant for medical use |
GB0715285D0 (en) * | 2007-08-06 | 2007-09-12 | Britannia Pharmaceuticals Ltd | Improvements in or relating to powdered medicaments for nasal delivery |
GB0721394D0 (en) * | 2007-10-31 | 2007-12-12 | Vectura Group Plc | Compositions for trating parkinson's disease |
WO2009132227A1 (en) * | 2008-04-24 | 2009-10-29 | Medtronic, Inc. | Protective gel based on chitosan and oxidized polysaccharide |
AU2009240513B2 (en) | 2008-04-24 | 2015-03-26 | Medtronic, Inc. | Chitosan-containing protective composition |
WO2009132224A2 (en) | 2008-04-24 | 2009-10-29 | Medtronic, Inc. | Rehydratable thiolated polysaccharide particles and sponge |
CN102099060A (en) | 2008-04-24 | 2011-06-15 | 麦德托尼克公司 | Cold ionizing radiation sterilization |
US20100086576A1 (en) * | 2008-10-06 | 2010-04-08 | Myntti Matthew F | Antimicrobial composition and methods of making and using same |
EP2706845B1 (en) | 2011-05-10 | 2021-06-23 | Next Science IP Holdings Pty Ltd | Antimicrobial solid and methods of making and using same |
AU2014293141A1 (en) | 2013-07-23 | 2016-02-18 | Serenity Pharmaceuticals Llc | Methods and compositions comprising desmopressin in combination with a beta-3 adrenergic receptor agonist |
CN106233141B (en) | 2014-02-18 | 2018-08-21 | 罗伯特·I·汉金 | The method and composition of loss and/or distortion for the diagnosing and treating sense of taste or smell |
US10286033B2 (en) * | 2014-11-20 | 2019-05-14 | Serenity Pharmaceuticals, Llc | Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist |
WO2017168174A1 (en) | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | New pharmaceutical forms of sildenafil |
WO2023133463A1 (en) * | 2022-01-06 | 2023-07-13 | Cyrano Therapeutics, Inc. | Improved nasal administration of parkinson's therapeutics |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988004926A1 (en) * | 1987-01-08 | 1988-07-14 | Nastech Pharmaceutical Company, Inc. | Nasal delivery of amino acids |
WO1994022445A2 (en) * | 1993-03-26 | 1994-10-13 | Merkus Franciscus W H M | Pharmaceutical compositions for intranasal administration of dihydroergotamine, apomorphine and morphine |
US5804212A (en) * | 1989-11-04 | 1998-09-08 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
WO1998047535A1 (en) * | 1997-04-18 | 1998-10-29 | West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited | Improved delivery of drugs to mucosal surfaces |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62123112A (en) | 1985-11-22 | 1987-06-04 | Sunstar Inc | Ointment base |
DE3601132A1 (en) | 1986-01-16 | 1987-07-23 | Christian Bannert | METHOD FOR TREATING THE MUCUS |
JPS62236862A (en) | 1986-04-09 | 1987-10-16 | Nippon Kayaku Co Ltd | Artificial mucus |
US4826683A (en) * | 1987-01-09 | 1989-05-02 | Bates Harry L | Decongestant |
FR2614021B1 (en) * | 1987-04-14 | 1991-03-01 | Andre Buzas | 1 - ((1,1-DIPHENYL) -1-ALCENYL) -PIPERAZINE DERIVATIVES, PROCESS FOR OBTAINING AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
US4915948A (en) | 1987-08-31 | 1990-04-10 | Warner-Lambert Company | Tablets having improved bioadhesion to mucous membranes |
DE3827561C1 (en) | 1988-08-13 | 1989-12-28 | Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De | |
JPH0436233A (en) * | 1990-05-29 | 1992-02-06 | Biomaterial Universe Kk | Sustained release preparation containing physiologically active substance and decomposable and absorbable in living body |
JPH0597706A (en) | 1991-04-09 | 1993-04-20 | Chemex Block Drug Jv | Method for treating aphthosis ulcer and other mucous skin membrane trouble |
IT1250691B (en) * | 1991-07-22 | 1995-04-21 | Giancarlo Santus | THERAPEUTIC COMPOSITIONS FOR INTRANASAL ADMINISTRATION INCLUDING KETOROLAC. |
US5318780A (en) | 1991-10-30 | 1994-06-07 | Mediventures Inc. | Medical uses of in situ formed gels |
WO1994022460A1 (en) * | 1993-04-05 | 1994-10-13 | University Patents, Inc. | Diagnosis and treatment of erectile dysfunction |
NZ250844A (en) * | 1993-04-07 | 1996-03-26 | Pfizer | Treatment of non-insulin dependant diabetes with peptides; composition |
GB9310412D0 (en) * | 1993-05-20 | 1993-07-07 | Danbiosyst Uk | Nasal nicotine system |
EP0792161A4 (en) * | 1993-07-12 | 1998-04-29 | Virus Res Inst | Hydrogel microencapsulated vaccines |
JP3696265B2 (en) * | 1994-02-04 | 2005-09-14 | 日本オルガノン株式会社 | Nasal solution |
WO1995028930A1 (en) * | 1994-04-22 | 1995-11-02 | Pentech Pharmaceuticals, Inc. | Dosage forms and method for ameliorating male erectile dysfunction |
GB9414966D0 (en) * | 1994-07-26 | 1994-09-14 | Danbiosyst Uk | Pharmaceutical compositions for the nasal administration of antiviral agents |
-
1998
- 1998-11-27 AR ARP980106027A patent/AR017694A1/en unknown
- 1998-11-27 DK DK98955814T patent/DK1035833T3/en active
- 1998-11-27 EP EP98955814A patent/EP1035833B1/en not_active Expired - Lifetime
- 1998-11-27 CA CA002312839A patent/CA2312839C/en not_active Expired - Fee Related
- 1998-11-27 AT AT98955814T patent/ATE303131T1/en active
- 1998-11-27 WO PCT/GB1998/003572 patent/WO1999027905A1/en active IP Right Grant
- 1998-11-27 ES ES98955814T patent/ES2249846T3/en not_active Expired - Lifetime
- 1998-11-27 DE DE69831421T patent/DE69831421T2/en not_active Expired - Lifetime
- 1998-11-27 JP JP2000522892A patent/JP4754067B2/en not_active Expired - Fee Related
- 1998-11-27 AU AU12535/99A patent/AU751182B2/en not_active Ceased
- 1998-11-27 NZ NZ504786A patent/NZ504786A/en not_active IP Right Cessation
-
2000
- 2000-06-02 US US09/586,139 patent/US6342251B1/en not_active Expired - Lifetime
- 2000-06-02 NO NO20002851A patent/NO329381B1/en not_active IP Right Cessation
-
2001
- 2001-08-01 US US09/920,698 patent/US20010046519A1/en not_active Abandoned
-
2010
- 2010-10-07 JP JP2010227620A patent/JP2011026341A/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988004926A1 (en) * | 1987-01-08 | 1988-07-14 | Nastech Pharmaceutical Company, Inc. | Nasal delivery of amino acids |
US5804212A (en) * | 1989-11-04 | 1998-09-08 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
WO1994022445A2 (en) * | 1993-03-26 | 1994-10-13 | Merkus Franciscus W H M | Pharmaceutical compositions for intranasal administration of dihydroergotamine, apomorphine and morphine |
WO1998047535A1 (en) * | 1997-04-18 | 1998-10-29 | West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited | Improved delivery of drugs to mucosal surfaces |
Cited By (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0967214A1 (en) * | 1998-06-22 | 1999-12-29 | Pfizer Limited | Intranasal formulations for treating sexual disorders |
AP1178A (en) * | 1998-06-22 | 2003-06-30 | Pfizer Ireland Pharmaceuticals | Intranasal formulations for treating sexual disorders |
WO1999066933A1 (en) * | 1998-06-25 | 1999-12-29 | New Millennium Pharmaceutical Research, Inc. | Nasal administration of sildenafil for the treatment of erectile dysfunction |
US6200591B1 (en) | 1998-06-25 | 2001-03-13 | Anwar A. Hussain | Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction |
WO2000007596A1 (en) * | 1998-07-31 | 2000-02-17 | Hexal Ag | Water-soluble pharmaceutical formulation for administering sildenafil |
WO2000007597A1 (en) * | 1998-07-31 | 2000-02-17 | Hexal Ag | Transmucosal therapeutic system for administering sildenafil |
US6740660B2 (en) | 1998-08-14 | 2004-05-25 | Nastech Pharmaceutical Company, Inc. | Nasal delivery of apomorphine |
US6436950B1 (en) | 1998-08-14 | 2002-08-20 | Nastech Pharmaceutical Company, Inc. | Nasal delivery of apomorphine |
WO2000059491A2 (en) * | 1999-04-06 | 2000-10-12 | Zonagen, Inc. | Methods for modulating the human sexual response |
WO2000059491A3 (en) * | 1999-04-06 | 2002-05-02 | Zonagen Inc | Methods for modulating the human sexual response |
WO2000076509A1 (en) * | 1999-06-16 | 2000-12-21 | Nastech Pharmaceutical Company, Inc. | Nasal delivery of apomorphine |
WO2001074358A1 (en) * | 2000-03-20 | 2001-10-11 | Tap Pharmaceutical Products Inc. | Methods for treating sexual dysfunction with apomorphine at specified plasma concentration levels |
US6506765B2 (en) | 2000-04-07 | 2003-01-14 | Tap Pharmaceutical Products, Inc. | Apomorphine derivatives and methods for their use |
JP2003534286A (en) * | 2000-05-26 | 2003-11-18 | ホーファー リサーチ リミテッド | Use of proanthocyanidin as an active ingredient of a stimulant and L-arginine or a salt thereof as a source of nitric oxide for improving erectile dysfunction symptoms |
WO2002024202A1 (en) * | 2000-09-19 | 2002-03-28 | Nastech Pharmaceutical Company, Inc. | Nasal delivery of apomorphine in combination with glycol derivatives |
WO2002067897A3 (en) * | 2001-02-28 | 2003-05-01 | Carrington Lab Inc | In-situ gel formation of pectins |
WO2002067897A2 (en) * | 2001-02-28 | 2002-09-06 | Carrington Laboratories, Inc. | In-situ gel formation of pectins |
US8551501B2 (en) | 2001-08-16 | 2013-10-08 | Mucovax Inc. | Chitin microparticles and their medical uses |
US7498038B2 (en) | 2001-08-16 | 2009-03-03 | Cmp Therapeutics Limited | Chitin microparticles and their medical uses |
EP1448194A1 (en) * | 2001-10-23 | 2004-08-25 | Pentech Pharmaceuticals, Inc. | Apomorphine-containing dosage form for ameliorating male erectile dysfunction |
EP1448194A4 (en) * | 2001-10-23 | 2005-08-10 | Pentech Pharmaceuticals Inc | Apomorphine-containing dosage form for ameliorating male erectile dysfunction |
WO2003080022A2 (en) * | 2002-03-19 | 2003-10-02 | Ionix Pharmaceuticals Limited | Analgesics for nasal administration |
US7666876B2 (en) | 2002-03-19 | 2010-02-23 | Vernalis (R&D) Limited | Buprenorphine formulations for intranasal delivery |
WO2003080021A3 (en) * | 2002-03-19 | 2003-12-31 | Ionix Pharmaceuticals Ltd | Formulation comprising buprenorphine |
WO2003080022A3 (en) * | 2002-03-19 | 2004-05-13 | Ionix Pharmaceuticals Ltd | Analgesics for nasal administration |
GB2397016A (en) * | 2002-03-19 | 2004-07-14 | Ionix Pharmaceuticals Ltd | Intranasal analgesic composition comprising buprenorphine, & preferably chitosan or partially esterified pectin |
GB2397016B (en) * | 2002-03-19 | 2004-10-27 | Ionix Pharmaceuticals Ltd | Intranasal analgesic composition containing buprenorphine |
WO2003080021A2 (en) * | 2002-03-19 | 2003-10-02 | Ionix Pharmaceuticals Limited | Formulation comprising buprenorphine |
KR101030403B1 (en) | 2002-03-19 | 2011-04-20 | 아르키메데스 디벨로프먼트 리미티드 | Formulation comprising buprenorphine |
US8889176B2 (en) | 2003-01-10 | 2014-11-18 | Depomed, Inc. | Method of managing or treating pain |
US9814705B2 (en) | 2003-01-10 | 2017-11-14 | Depomed, Inc. | Intranasal spray device containing pharmaceutical composition |
US9078814B2 (en) | 2003-01-10 | 2015-07-14 | Depomed, Inc. | Intranasal spray device containing pharmaceutical composition |
WO2005041966A1 (en) * | 2003-10-24 | 2005-05-12 | Nastech Pharmaceutical Company Inc. | Treatment of parkinson's disease using apomorphine in combination with an apomorphine prodrug |
WO2007059390A1 (en) * | 2005-11-14 | 2007-05-24 | Medtronic Xomed, Inc. | Injectable formulation capable of forming a drug-releasing device |
AU2006315238B2 (en) * | 2005-11-14 | 2012-11-01 | Medtronic Xomed, Inc. | Injectable formulation capable of forming a drug-releasing device |
WO2009040595A1 (en) * | 2007-09-28 | 2009-04-02 | Wockhardt Research Centre | Multi-dose pharmaceutical composition of analgesic for nasal administration |
US8309108B2 (en) | 2007-11-09 | 2012-11-13 | Archimedes Development Limited | Intranasal compositions |
AU2008326220B2 (en) * | 2007-11-09 | 2013-05-23 | Archimedes Development Limited | Intranasal compositions |
TWI426928B (en) * | 2007-11-09 | 2014-02-21 | Archimedes Dev Ltd | Intranasal compositions |
WO2009060226A1 (en) * | 2007-11-09 | 2009-05-14 | Archimedes Development Limited | Intranasal compositions |
KR101522529B1 (en) * | 2007-11-09 | 2015-05-26 | 아르키메데스 디벨로프먼트 리미티드 | Intranasal compositions |
EP2057982A1 (en) | 2007-11-09 | 2009-05-13 | Archimedes Development Limited | Intranasal compositions |
US9700344B2 (en) | 2008-06-12 | 2017-07-11 | Medtronic Xomed, Inc. | Method for treating chronic wounds with an extracellular polymeric substance solvating system |
WO2011063775A2 (en) | 2009-11-25 | 2011-06-03 | Zentiva, K.S. | Pectin complexes of sartans and pharmaceutical compositions based thereon |
WO2011063774A2 (en) | 2009-11-25 | 2011-06-03 | Zentiva, K.S. | Pectin complexes of steroids and pharmaceutical compositions based thereon |
FR3032619A1 (en) * | 2015-02-12 | 2016-08-19 | Laboratoires Chemineau | PLANT-BASED COMPOSITION OF MALVACEAE FAMILY FOR NASAL CAVITY ADMINISTRATION |
EP3056219A1 (en) * | 2015-02-12 | 2016-08-17 | Laboratoires Chemineau | Composition based on plants of the malvaceae family for mucosal delivery |
Also Published As
Publication number | Publication date |
---|---|
NO20002851D0 (en) | 2000-06-02 |
US20010046519A1 (en) | 2001-11-29 |
DE69831421T2 (en) | 2006-06-22 |
JP4754067B2 (en) | 2011-08-24 |
CA2312839A1 (en) | 1999-06-10 |
NO329381B1 (en) | 2010-10-04 |
ATE303131T1 (en) | 2005-09-15 |
AU1253599A (en) | 1999-06-16 |
NO20002851L (en) | 2000-06-02 |
DK1035833T3 (en) | 2006-01-09 |
AR017694A1 (en) | 2001-09-12 |
JP2011026341A (en) | 2011-02-10 |
JP2001524509A (en) | 2001-12-04 |
AU751182B2 (en) | 2002-08-08 |
DE69831421D1 (en) | 2005-10-06 |
NZ504786A (en) | 2005-07-29 |
ES2249846T3 (en) | 2006-04-01 |
CA2312839C (en) | 2008-01-15 |
US6342251B1 (en) | 2002-01-29 |
EP1035833B1 (en) | 2005-08-31 |
EP1035833A1 (en) | 2000-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1035833B1 (en) | Compositions for nasal administration | |
AU685458B2 (en) | Nasal drug delivery composition containing nicotine | |
JP4880657B2 (en) | Improved drug delivery to mucosal surfaces | |
AU757786B2 (en) | Formulations of fexofenadine | |
JP5890951B2 (en) | Aqueous drug delivery system with an unpleasant taste masking agent | |
JPH10502390A (en) | Sustained release matrix for pharmaceuticals | |
WO2005079749A2 (en) | Chitosan containing solution | |
WO2008054081A1 (en) | Hyaluronic acid and hydrophobic poly amino acid copolymer | |
CN101756982A (en) | Artesunate compound medicine composition with improved mouth feeling and high stability | |
CN114555060A (en) | Ion exchange compositions with water-soluble mucoadhesive polymers | |
ES2962546T3 (en) | Compositions for oral administration of pentosan polysulfate in the form of nanoparticles with improved intestinal absorption | |
WO2018113916A1 (en) | A mucoadhesive oromucosal formulation comprising a nicotine complex | |
Salis | Polysaccharides as Drug Delivery Systems for different Administration Routes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1998955814 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 504786 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12535/99 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2312839 Country of ref document: CA Ref country code: CA Ref document number: 2312839 Kind code of ref document: A Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09586139 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1998955814 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 12535/99 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998955814 Country of ref document: EP |